SMAART II Study Testing a Daily Polypill to Reduce Stroke-Related Vascular Risks Over 24 Months in Adults
Led by Northern California Institute of Research and Education · Updated on 2026-07-06
1000
Participants Needed
4
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the Stroke Minimization through Additive Anti-atherosclerotic Agents in Routine Treatment II SMAART-II study, which aims to test a polypill strategy to reduce vascular risk in patients who recently experienced a stroke. This Phase 3 trial seeks to compare the effectiveness of a fixed-dose combination pill against usual care over 24 months, with a focus on improving cardiovascular outcomes in an under-resourced healthcare setting in Ghana.
The study involves two groups one receiving the polypill Polycapae, which combines aspirin, simvastatin, hydrochlorothiazide, ramipril, and atenolol taken as two capsules once daily, and the other receiving standard care with treatments at the discretion of their doctors. Patients already on similar medications will have their treatments replaced by the polypill if assigned to that group. Both groups providers receive training on recommended biomarker targets for stroke secondary prevention.
Participants will be monitored for up to 24 months, with regular assessments of vascular risk factor control, adherence to medical therapy, safety, and quality of life using specific health-related questionnaires. Researchers will track major adverse cardiovascular events and measure composite vascular risk at 12 and 24 months. The study includes safety and tolerability monitoring throughout the period and aims to develop strategies for integrating this treatment approach into routine care.
CONDITIONS
Brief Title
Stroke Minimization Through Additive Anti-atherosclerotic Agents in Routine Treatment II Study (SMAART II)
Research Team
B
Bruce Ovbiagele, MD
R
Raelle Tagge, MPH
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Northern California Institute of Research and Education
Lead Sponsor
Who Can Participate
Age: 18Years - 100Years
All Genders
Eligibility Criteria
You may qualify if you...
Above the age of 18 years; male or female
Ischemic stroke diagnosis no greater than two months before enrollment
Ischemic strokes including lacunar, large-vessel atherosclerotic, cardio-embolic subtypes are eligible
Presence of at least one of the following: documented diabetes mellitus or prior treatment with oral hypoglycemics or insulin; documented hypertension greater than 140/90 mmHg or prior use of antihypertensives; mild to moderate renal dysfunction (eGFR 60-30 ml/min/1.73m2); prior myocardial infarction
Legally competent to sign informed consent
You will not qualify if you...
Unable to sign informed consent
Contraindications to any components of the polypill
Hemorrhagic stroke
Severe cognitive impairment, dementia, or severe disability limiting self-care
Severe congestive cardiac failure (NYHA III-IV)
Severe renal disease (eGFR less than 30 ml/min/1.73m2), renal dialysis, awaiting or received renal transplant
Cancer diagnosis or treatment within past 2 years
Need for oral anticoagulation now or planned in the near future
Significant arrhythmias including unresolved ventricular arrhythmias or atrial fibrillation
Nursing or pregnant mothers
Do not agree to the use of pseudonymized data
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Treatment
Duration - 24 months
Participants receive either the Polycap polypill or usual care for secondary stroke prevention. Those assigned to Polycap take two capsules orally once daily, replacing prior antihypertensive, lipid-lowering, and antithrombotic medications if applicable. Usual care is managed by physicians with guideline training.
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Similar Trials
Study Evaluating Combined Cognitive and Balance Rehabilitation for Adults Recovering From Stroke
Using 5T MRI and Metabolomics to Predict Hemorrhage Risk in Moyamoya Disease A Prospective Observational Cohort Study
Testing Caregiver-Assisted Strategy Training to Improve Daily Activities for Adults After Stroke in a Multi-Center Trial
Stroke Recovery Study Using EEG-Guided Muscle and Tongue Stimulation
Evaluating Brain-Computer Interface and Functional Electric Stimulation Therapy
Digital Intervention to Improve Depression and Executive Function After Stroke Using AKL-T01 and Coaching
Smart Home-Based Upper Limb Rehabilitation Using Robot and Task Training for Adults with Stroke and Spinal Cord Injuries
Study of Brain Activity Using Functional Near-Infrared Spectroscopy in Stroke Patients During Mirror Movement
Using a Mobile BrainBody Imaging System to Improve Post-Stroke Walking with a Robotic Device
Testing Viral Combat, a Mobile Game to Help Improve PrEP Medication Adherence
A Randomized Trial with Participants Aged 15 to 34 Receiving PrEP Care in New England and Mississippi
Study on Intravenous Thrombolysis Using Alteplase or Tenecteplase for Acute Ischemic Stroke Treated Between 4.5 and 24 Hours After Onset
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Stroke minimization through additive anti-atherosclerotic agents in routine treatment (SMAART) II: Rationale for a multi-country polypill phase 3 trial in sub-Saharan Africa.
Fred Stephen Sarfo, Kolawole Wahab, Sarah Shali Matuja...